Abstract β-DN 4-hydroxycytidine (NHC, EIDD-1931) is a nucleoside analogue that exhibits
broad spectrum antiviral activity against a variety of RNA viruses. Herein, we report the …

The spread of COVID-19 infection continues due to the emergence of multiple transmissible
and immune-evasive variants of the SARS-CoV-2 virus. Although various vaccines have …

Drug repurposing approach was applied to find a potent antiviral agent against RNA viruses
such as SARS-CoV-2, influenza viruses and dengue virus with a concise strategy of small …

ABSTRACT Remdesivir (RDV; GS-5734) is currently the only FDA-approved antiviral drug
for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …

The spread of COVID-19 continues due to genetic variation in SARS-CoV-2. Highly mutated
variants of SARS-CoV-2 have an increased transmissibility and immune evasion. Due to the …

The current focus for many researchers has turned to the development of therapeutics that
have the potential for serving as broad-spectrum inhibitors that can target numerous viruses …

The nucleoside metabolite of remdesivir, GS-441524 displays potent anti-SARS-CoV-2
efficacy, and is being evaluated in clinical as an oral antiviral therapeutic for COVID-19 …

Coronaviruses (CoVs) are positive-sense RNA enveloped viruses, members of the family
Coronaviridae, that cause infections in a broad range of mammals including humans …

We report here the synthesis, purification, and characterization of mono-and di-fatty acyl
conjugates of remdesivir (RDV) and their in vitro antiviral activity against SAR-CoV-2, an …

Broad spectrum oral antivirals are urgently needed for the early treatment of many RNA
viruses of clinical concern. We previously described the synthesis of 1-O-octadecyl-2-O …